Donald Brautigam, MD
Family Medicine · Westfield, NYNPI 1407821986
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 58.1% of the total. Reporting peaked in 2023 at $6,170 and has fallen 98.7% since, to $80 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $161.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$6K
- Eli Lilly$3K
- Novo Nordisk AS$1K
- GSK$91
- Pfizer$86
- AstraZeneca$60
- plus $322 from 13 others
Across 3,011 payments — averaging $434.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$960K
- Eli Lilly$292K
- Lexicon Pharmaceuticals, Inc.$43K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boehringer Ingelheim$6K
- Boehringer Ingelheim International GmbH$372
- plus $25 from 1 others
What the payments were for
- Consulting fees$5,15648%
- Travel & lodging$4,24540%
- Food & beverage$1,28912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $6,207 |
| Eli Lilly | 14 | $2,861 |
| Novo Nordisk AS | 4 | $1,062 |
| GSK | 5 | $91 |
| Pfizer | 5 | $86 |
| AstraZeneca | 4 | $60 |
| Lilly USA, LLC | 4 | $60 |
| Bayer | 2 | $47 |
| Amgen | 2 | $34 |
| Boston Scientific | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Advanced Oxygen Therapy Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Abbott | 1 | $12 |
How this compares
$10,690 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $50,383 |
| Victoza 3-PakLiraglutide | 27 | $33,990 |
| JardianceEmpagliflozin | 34 | $32,152 |
| MounjaroTirzepatide | 21 | $23,394 |
| OzempicSemaglutide | 14 | $22,550 |
| TrulicityDulaglutide | 19 | $19,588 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $11,476 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,508 |
| Atorvastatin Calcium | 192 | $2,262 |
| Metoprolol Succinate | 83 | $1,485 |
| Levothyroxine Sodium | 97 | $1,438 |
| Lisinopril | 189 | $1,241 |
| Rosuvastatin Calcium | 76 | $1,228 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $1,024 |
| Valsartan | 46 | $927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $50,38342 claims |
| Lilly USA, LLCMounjaro, Trulicity | $60 | $42,98140 claims |
| Novo NordiskOzempic | $6,207 | $22,55014 claims |
| GSKTrelegy Ellipta | $91 | $9,50811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Westfield
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.